investigational new drug

Can Preclinical Data Guide Clinical Cancer Therapy?

A Q&A with Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital; kflaherty@mgh.harvard.edu Originally published Aug 31, 2016 Q: Under what circumstances and to what extent are you willing to take clinical actions on a cancer patient based primarily on preclinical data? A: There are two scenarios that come to mind when thinking about… Read more »